

Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases

Horizon Europe

● IN ATTESA

Codice

HORIZON-HLTH-2027-02-TOOL-01-two-stage

Ambito

Internazionale

Località

Europa

Curatore

Marlene Faria

DETTAGLI FINANZIARI

Tipo di supporto

Fondo perduto

Tasso Massimo di Finanziamento

100%

Budget

44.2M€

Valore di Progetto Ammissibile

6M€ - 8M€

DATE E SCADENZE

Data di Pubblicazione

19 ottobre 2026

Data di Apertura

29 ottobre 2026

Fase 1

17 febbraio 2027 alle ore 17:00 GMT+1

Fase 2

16 settembre 2027 alle ore 17:00 GMT+2

DESCRIZIONE

Objectives

This topic aims to develop and clinically validate predictive biomarkers of disease progression and treatment response for chronic Non-Communicable Diseases, excluding cancer. The action seeks to move beyond the traditional single-biomarker approach by using trustworthy Artificial Intelligence methodologies to combine multiple clinical, biological and digital data sources.

The expected results should enable more accurate disease monitoring, support personalised treatment decisions and improve clinical research and patient outcomes. Clinicians and healthcare professionals should ultimately have access to validated biomarkers and AI tools with demonstrably greater accuracy and clinical value than current practice.

Funding

Funding is provided under a Horizon Europe Research and Innovation Action (RIA). The topic has an indicative budget of €44.2 million, with approximately six projects expected to be funded. The anticipated EU contribution ranges between €6 million and €8 million per project, although proposals requesting different amounts may be considered where appropriately justified. As an RIA, projects may receive funding of up to 100% of eligible costs, in accordance with Horizon Europe rules.

The call follows a two-stage submission procedure, opening on 29 October 2026, with a first-stage deadline of 17 February 2027 and a second-stage deadline of 16 September 2027.

SPESE AMMISSIBILI

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

IDONEITÀ

Modalità di Candidatura

Aggregata / Partenariato

Settori Idonei

- Salute e Life Sciences
- ICT e Software
- Industria

Tipologie Aziendali

- Microimpresa
- PMI
- Small Mid-Cap
- Mid-Cap
- Grande impresa
- Enti di ricerca
- Enti privati non profit
- Enti pubblici

Tipi di Azione

- Development of health technologies
- Digital health solutions

- Biomedical research
- Artificial Intelligence for health
- Data-driven healthcare
- Prevention and diagnosis
- Personalized medicine
- Patient monitoring
- Research and Innovation Action

DETTAGLI PROGRAMMA UE

ID Bando	Cluster
HORIZON-HLTH-2027-02-TOOL-01-two-stage	Health
Destinazione	Modalità di Presentazione
D5. Developing and using new tools, technologies and digital solutions for a healthy society	Two-stage
Contributo UE	Progetti Previsti
Around €6,000,000.00 to €8,000,000.00 per project	6
Regola del Tasso di Finanziamento	
Up to 100% of eligible costs for Research and Innovation Actions (RIA)	

LINK UFFICIALI

Regolamento Ufficiale

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-02-TOOL-01-two-stage?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-HLTH-2027-02-TOOL-01-two-stage&isExactMatch=true&status=31094501,31094502,31094503>

Pagina Grantavia

<https://grantavia.com/it/incentives/development-of-predictive-biomarkers-of-disease-progression-and-treatment-response-by-using-ai-methodologies-for-chronic-non-communicable-diseases>

Prenota un incontro

<https://bookings.cloud.microsoft/book/Prenotaunappuntamento@epsa.com/?ismsaljsauthenabled>